Sue Desmond-Hellmann speaks at the Milken Institute Global Conference in Beverly Hills, April 2019 (via Bloomberg/Getty Images)

Sue Desmond-Hell­mann joins the mar­quee crowd of bio­phar­ma ex­perts at GV boot­ing up a new gen­er­a­tion of drug hunters

Sue Desmond-Hell­mann has start­ed the next chap­ter of her sto­ried ca­reer in bio­phar­ma.

GV — the ven­ture group for­mer­ly known as Google Ven­tures — has opened its doors to add her to their list of mar­quee drug ex­perts.

David Schenkein, who made the leap to GV af­ter start­ing from scratch to build Agios in­to a com­mer­cial-stage biotech in 10 years, of­fered his thumbs-up on Twit­ter af­ter GV put out the word on­line that Desmond-Hell­mann would be join­ing them as a se­nior ad­vis­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.